116 related articles for article (PubMed ID: 38556044)
1. Erianin serves as an NFATc1 inhibitor to prevent breast cancer-induced osteoclastogenesis and bone destruction.
Zheng J; He W; Chen Y; Li L; Liang Q; Dai W; Li R; Chen F; Chen Z; Tan Y; Li X
J Adv Res; 2024 Mar; ():. PubMed ID: 38556044
[TBL] [Abstract][Full Text] [Related]
2. Oroxylin A suppresses breast cancer-induced osteoclastogenesis and osteolysis as a natural RON inhibitor.
Chen Y; Zheng J; Mo L; Chen F; Li R; Wang Y; Liang Q; Chen Z; Dai W; Chen L; Yan P; Zhou H; Li X
Phytomedicine; 2024 Jul; 129():155688. PubMed ID: 38728920
[TBL] [Abstract][Full Text] [Related]
3. Gold clusters prevent breast cancer bone metastasis by suppressing tumor-induced osteoclastogenesis.
Zhang Z; Yao Y; Yuan Q; Lu C; Zhang X; Yuan J; Hou K; Zhang C; Du Z; Gao X; Chen X
Theranostics; 2020; 10(9):4042-4055. PubMed ID: 32226538
[No Abstract] [Full Text] [Related]
4. Polyphyllin VII protects from breast cancer-induced osteolysis by suppressing osteoclastogenesis via c-Fos/NFATc1 signaling.
Yang Q; Guo J; Zheng J; Chen Y; Zou B; Li R; Ding Z; Wang Y; Li L; Chen Z; Mo L; Liang Q; Chen F; Li X
Int Immunopharmacol; 2023 Jul; 120():110316. PubMed ID: 37253315
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1.
Takatsuna H; Asagiri M; Kubota T; Oka K; Osada T; Sugiyama C; Saito H; Aoki K; Ohya K; Takayanagi H; Umezawa K
J Bone Miner Res; 2005 Apr; 20(4):653-62. PubMed ID: 15765185
[TBL] [Abstract][Full Text] [Related]
6. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
7. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of PPP1R15A alleviates osteoporosis via suppressing RANKL-induced osteoclastogenesis.
Ding ZB; Chen Y; Zheng YR; Wang YY; Deng WD; Zheng JH; Yang Q; Chen ZY; Li LH; Jiang H; Li XJ
Acta Pharmacol Sin; 2024 Apr; 45(4):790-802. PubMed ID: 38191913
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological inhibition of protein S-palmitoylation suppresses osteoclastogenesis and ameliorates ovariectomy-induced bone loss.
Ma L; Zhang L; Liao Z; Xiu C; Luo X; Luo N; Zhang L; He G; Chen J
J Orthop Translat; 2023 Sep; 42():1-14. PubMed ID: 37521493
[TBL] [Abstract][Full Text] [Related]
10. CTRP3 acts as a negative regulator of osteoclastogenesis through AMPK-c-Fos-NFATc1 signaling in vitro and RANKL-induced calvarial bone destruction in vivo.
Kim JY; Min JY; Baek JM; Ahn SJ; Jun HY; Yoon KH; Choi MK; Lee MS; Oh J
Bone; 2015 Oct; 79():242-51. PubMed ID: 26103094
[TBL] [Abstract][Full Text] [Related]
11. Isofraxidin Inhibits Receptor Activator of Nuclear Factor-κB Ligand-Induced Osteoclastogenesis in Bone Marrow-Derived Macrophages Isolated from Sprague-Dawley Rats by Regulating NF-κB/NFATc1 and Akt/NFATc1 Signaling Pathways.
Wang W; Wang B
Cell Transplant; 2021; 30():963689721990321. PubMed ID: 33573387
[TBL] [Abstract][Full Text] [Related]
12. Dendrobine attenuates osteoclast differentiation through modulating ROS/NFATc1/ MMP9 pathway and prevents inflammatory bone destruction.
Deng W; Ding Z; Wang Y; Zou B; Zheng J; Tan Y; Yang Q; Ke M; Chen Y; Wang S; Li X
Phytomedicine; 2022 Feb; 96():153838. PubMed ID: 34801352
[TBL] [Abstract][Full Text] [Related]
13. Agrimophol suppresses RANKL-mediated osteoclastogenesis through Blimp1-Bcl6 axis and prevents inflammatory bone loss in mice.
Cao J; Wang S; Wei C; Lin H; Zhang C; Gao Y; Xu Z; Cheng Z; Sun WC; Wang HB
Int Immunopharmacol; 2021 Jan; 90():107137. PubMed ID: 33199235
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of receptor activator of nuclear factor-κB ligand- or lipopolysaccharide-induced osteoclast formation by conophylline through downregulation of CREB.
Koide N; Kondo Y; Odkhuu E; Ulziisaikhan J; Ukaji T; Yokochi T; Umezawa K
Immunol Lett; 2014 Sep; 161(1):31-7. PubMed ID: 24792671
[TBL] [Abstract][Full Text] [Related]
15. Neogambogic Acid Suppresses Receptor Activator of Nuclear Factor κB Ligand (RANKL)-Induced Osteoclastogenesis by Inhibiting the JNK and NF-κB Pathways in Mouse Bone Marrow-Derived Monocyte/Macrophages.
Jin G; Wang FF; Li T; Jia DD; Shen Y; Xu HC
Med Sci Monit; 2018 Apr; 24():2569-2577. PubMed ID: 29698379
[TBL] [Abstract][Full Text] [Related]
16. Hispidulin attenuates bone resorption and osteoclastogenesis via the RANKL-induced NF-κB and NFATc1 pathways.
Nepal M; Choi HJ; Choi BY; Yang MS; Chae JI; Li L; Soh Y
Eur J Pharmacol; 2013 Sep; 715(1-3):96-104. PubMed ID: 23791609
[TBL] [Abstract][Full Text] [Related]
17. Hypericin targets osteoclast and prevents breast cancer-induced bone metastasis via NFATc1 signaling pathway.
Ouyang Z; Guo X; Chen X; Liu B; Zhang Q; Yin Z; Zhai Z; Qu X; Liu X; Peng D; Shen Y; Liu T; Zhang Q
Oncotarget; 2018 Jan; 9(2):1868-1884. PubMed ID: 29416737
[TBL] [Abstract][Full Text] [Related]
18. Homer2 and Homer3 modulate RANKL-induced NFATc1 signaling in osteoclastogenesis and bone metabolism.
Son A; Kang N; Oh SY; Kim KW; Muallem S; Yang YM; Shin DM
J Endocrinol; 2019 Sep; 242(3):241-249. PubMed ID: 31319381
[TBL] [Abstract][Full Text] [Related]
19. Licorice isoliquiritigenin suppresses RANKL-induced osteoclastogenesis in vitro and prevents inflammatory bone loss in vivo.
Zhu L; Wei H; Wu Y; Yang S; Xiao L; Zhang J; Peng B
Int J Biochem Cell Biol; 2012 Jul; 44(7):1139-52. PubMed ID: 22521613
[TBL] [Abstract][Full Text] [Related]
20. IL-11 produced by breast cancer cells augments osteoclastogenesis by sustaining the pool of osteoclast progenitor cells.
McCoy EM; Hong H; Pruitt HC; Feng X
BMC Cancer; 2013 Jan; 13():16. PubMed ID: 23311882
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
